ARA-290

ARA-290, also called cibinetide, is an 11-amino-acid peptide derived from the tertiary structure of erythropoietin (EPO). Unlike full-length EPO, ARA-290 has no effect on red blood cell production — it was specifically engineered to keep EPO's tissue-protective and anti-inflammatory actions while removing its hematopoietic activity. It binds the innate repair receptor (IRR), a heterocomplex of EPO receptor and the beta common receptor expressed on injured tissue. It is sold strictly for laboratory research.

Erythropoietin is famous for boosting red blood cell production — the thing endurance athletes (illegally) use to oxygenate their muscles. But EPO also has a quieter second job: it tells injured tissue to calm down inflammation and start repairing. ARA-290 is the stripped-down version that keeps only the repair signal. Researchers study it for nerve damage, chronic inflammation, and conditions like small-fiber neuropathy and sarcoidosis. It is one of the few peptides in this category with completed clinical trials in humans.

ARA-290 selectively activates the innate repair receptor (IRR), an EPO receptor isoform expressed mainly on damaged or stressed cells. Activation suppresses pro-inflammatory cytokines, reduces oxidative stress, and supports neuronal and tissue repair without raising hematocrit. This receptor-selective design avoids the cardiovascular risks associated with full EPO.

• •Small-fiber neuropathy and sarcoidosis pain
• •Diabetic neuropathy
• •Wound healing in diabetic models
• •Anti-inflammatory cytokine modulation
• •Innate repair receptor biology
• •Neuroprotection after ischemic injury

ARA-290 occupies a small but devoted corner of the chronic-pain and neuropathy internet. Patients with small-fiber neuropathy and sarcoidosis-related pain reference it frequently because of published clinical work showing symptom improvements. On r/Peptides, threads tend to be more measured than other categories — fewer 'gains' claims, more careful discussion of inflammation, neuropathy, and the published Araim Pharmaceuticals data.

“EPO without the blood-doping side.”

ARA-290 is rarely stacked aggressively. The most common combinations in research discussion are with BPC-157 or thymosin alpha-1 in chronic-pain or autoimmune contexts where multiple repair and immune pathways are theoretically involved.

ARA-290 (cibinetide) is an 11-amino-acid EPO-derived peptide that activates the innate repair receptor to reduce inflammation and support tissue repair without affecting red blood cell production. It has been studied in clinical trials for small-fiber neuropathy and sarcoidosis and is sold for laboratory research only.